Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
15/09/26	SEK 0.4535	-2.37%	2,138,827
14/09/26	SEK 0.4645	-1.28%	2,432,120
11/09/26	SEK 0.4705	-49.79%	14,424,697
10/09/26	SEK 0.9370	+3.31%	1,107,793
09/09/26	SEK 0.9070	-5.52%	2,702,989

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 09:11:57 15/09/26 pm AEST			5-day change	1st Jan Change
0.4535 ^SEK	-2.37%		-52.76%	-45.30%

12/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW

Market Cap	94.13M 9.64M 8.35M 7.88M 7.15M 13.41M 924M 13.51M 36.27M 469M 36.2M 35.4M 1.49B	P/E 2026 *	-1.72x	P/E 2027 *	-1.22x
Enterprise Value	78.13M 8M 6.93M 6.54M 5.93M 11.13M 767M 11.21M 30.11M 389M 30.05M 29.38M 1.24B	EV / Sales 2026 *	2.49x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

12/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
11/09	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
11/09	Asker plunges on choppy Stockholm market	FW
11/09	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
11/09	Alzinova AB Initiates Operational Start-Up Of Global Phase 2 Study With ALZ-101	CI
20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

11/09	Alzinova: Phase II study update and SEK51 rights issue	AQ
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital	AQ
11/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million	AQ
11/09	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101	AQ
24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ

1 day	-2.37%
1 week	-52.76%
Current month	-43.31%
1 month	-52.16%
3 months	-4.43%
6 months	-32.81%
Current year	-45.30%

1 week	0.45	1.04
1 month	0.45	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-2.37%	-52.76%	-61.37%	-85.83%	9.64M
LONZA GROUP AG	-0.45%	-4.17%	-2.63%	+7.12%	45.63B
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+530.14%	43.96B
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+24.75%	43.73B
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+78.25%	40.23B
CELLTRION, INC.	+0.34%	-4.03%	+9.34%	+38.90%	31.86B
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	17.4B
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+112.62%	16.62B
EUROFINS SCIENTIFIC SE	+0.89%	+2.28%	+15.44%	+31.54%	14.46B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+31.45%	13.04B
Average	-0.12%	-6.39%	+50.26%	+85.44%	26.69B
Weighted average by Cap.	+0.46%	-2.01%	+75.95%	+127.59%

	2026 *	2027 *
Net sales	31.35M 3.21M 2.78M 2.62M 2.38M 4.47M 308M 4.5M 12.08M 156M 12.06M 11.79M 496M	-
Net income	-4.45M -456K -395K -373K -338K -634K -43.67M -639K -1.71M -22.16M -1.71M -1.67M -70.44M	-77M -7.88M -6.83M -6.45M -5.85M -10.97M -756M -11.05M -29.67M -383M -29.61M -28.96M -1.22B
Net Debt	-16M -1.64M -1.42M -1.34M -1.22M -2.28M -157M -2.3M -6.17M -79.66M -6.15M -6.02M -253M	-19M -1.95M -1.69M -1.59M -1.44M -2.71M -186M -2.73M -7.32M -94.6M -7.31M -7.15M -301M